Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for full year of year ending December 31, 2022. For the year, the company expected Core revenues of JPY 1,150,000 million, core operating profit of JPY 440,000 million, Core net income of JPY 312,500 million, core earnings per share of JPY 190.00 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,026 JPY | -0.48% | -3.07% | -5.92% |
02:16pm | Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation | MT |
25/04 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.92% | 52.77B | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- 4519 Stock
- News Chugai Pharmaceutical Co., Ltd
- Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022